DYAX CORP Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2013-12-10: Form 8-K; Period of report 2013-12-04; Description 1.02 Termination of a Material Definitive Agreement; Details 1.02.
- 2013-10-22: Form 8-K; Period of report 2013-10-22; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2013-10-11: Form 8-K; Period of report 2013-10-09; Description 1.01 Entry into a Material Definitive Agreement; Details 1.01.
- 2013-10-08: Form 8-K; Period of report 2013-10-02; Description 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure; Details 7.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2013-12-10 | 8-K | 2013-12-04 | 1.02 Termination of a Material Definitive Agreement | 1.02 On December 4, 2013, CMIC HOLDINGS Co., Ltd. ("CMIC", formerly known as CMIC Co., Ltd.) provided written notice to Dyax of its intent to terminate the Product Development and License Agreement, dated September 28, 2010 (the "License Agreement"), under which Dyax granted CMIC rights to develop and commercialize ecallantide (marketed as Kalbitor® in the United States) for hereditary angioedema (HAE) in Japan. | a50766362.htm |
| 2013-10-22 | 8-K | 2013-10-22 | 2.02 Results of Operations and Financial Condition | 2.02 On October 22, 2013, Dyax Corp. issued a press release announcing its financial results for the quarter ended September 30, 2013. | a50734468.htm |
| 2013-10-11 | 8-K | 2013-10-09 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | v357216_8k.htm |
| 2013-10-08 | 8-K | 2013-10-02 | 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure | 7.01 In the webcast of an interview of Dyax management at the Leerink Swann Rare Disease Roundtable held on October 2, 2013, the Company discussed its updated financial guidance for annual net sales of KALBITOR® (ecallantide) for 2013, which management expects will be at the low end of its existing guidance for annual sales of $40-44 million. | v356956_8k.htm |
| 2013-08-29 | 8-K | 2013-08-23 | 1.02 Termination of a Material Definitive Agreement | 1.02 On August 23, 2013, Dyax Corp. (“Dyax”) and US Bioservices Corporation (“US Bio”) entered into the First Amendment (the “Amendment”) to the Hub Services Agreement between Dyax and US Bio entered into in February 2013. | a50699486.htm |
| 2013-07-30 | 8-K | 2013-07-25 | 7.01 Regulation FD Disclosure | 7.01 On July 25, 2013, Dyax Corp. ("Dyax") received clearance from the U.S. Food and Drug Administration ("FDA") for an Investigational New Drug application ("IND") to allow clinical testing of DX-2930, Dyax's fully human monoclonal antibody inhibitor of plasma kallikrein. | a50680253.htm |
| 2013-07-24 | 8-K | 2013-07-24 | 2.02 Results of Operations and Financial Condition | 2.02 On July 24, 2013, Dyax Corp. issued a press release announcing its financial results for the quarter ended June 30, 2013. | a50677160.htm |
| 2013-06-27 | 8-K | 2013-06-25 | 7.01 Regulation FD Disclosure | 7.01 On June 25, 2013, Dyax Corp. ("Dyax") filed an Investigational New Drug application ("IND") with the U.S. Food and Drug Administration ("FDA") to allow clinical testing of DX-2930, Dyax's fully human monoclonal antibody inhibitor of plasma kallikrein. | a50661322.htm |
| 2013-06-25 | 8-K | 2013-06-21 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | a50659745.htm |
| 2013-05-16 | 8-K | 2013-05-10 | 1.01 Entry into a Material Definitive Agreement; 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 5.03 Effective May 14, 2013, the Company amended its Amended and Restated Certificate of Incorporation, as amended, by filing with the Delaware Secretary of State a Certificate of Designation of Preferences, Rights and Limitations of Series 1 Convertible Preferred Stock (the “Certificate”) that, pursuant to the authority granted to and vested in the Board of Directors of the Company, created a Series 1 Convertible Preferred Stock, which series shall carry the designations, powers, preferences, rights, qualifications, limitations and restrictions described below. 8.01 On May 13, 2013, the Company issued a press release announcing the Offering, a copy of which is attached as Exhibit 99.1 hereto and incorporated by reference herein. | v345096_8k.htm |
| 2013-05-15 | 8-K | 2013-05-09 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 At the Annual Meeting held on May 9, 2013, the stockholders of the Company voted on the following two proposals, each of which is described in detail in the Company's definitive proxy statement filed with the Securities and Exchange Commission on April 12, 2013. | v345296_8k.htm |
| 2013-04-25 | 8-K | 2013-04-25 | 2.02 Results of Operations and Financial Condition | 2.02 On April 25, 2013, Dyax Corp. issued a press release announcing its financial results for the quarter ended March 31, 2013. | a50618624.htm |
| 2013-04-02 | 8-K | 2013-03-27 | 1.02 Termination of a Material Definitive Agreement | 1.02 On March 27, 2013, Dyax and Sigma Tau Rare Diseases S.A. entered into a termination agreement pursuant to which they terminated their Joint Development and License Agreement dated June 18, 2010, as amended to date (the "License Agreement"). | a50601853.htm |
| 2013-03-29 | 8-K | 2013-03-29 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events | 5.02 On March 29, 2013, Dyax Corp. (the “Company”) entered into a consulting agreement with Ivana Magovcevic-Liebisch, Ph.D., J.D., pursuant to which Dr. Magovcevic-Liebisch will serve as a consultant to the Company and provide consulting services related to the Company’s historical and ongoing commercial, business development, licensing and intellectual property activities. | a50600172.htm |
| 2013-03-08 | 8-K | 2013-03-04 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 7.01 Regulation FD Disclosure; 8.01 Other Events | 5.02 On March 8, 2013, Dyax Corp. announced that Ivana Magovcevic-Liebisch, Ph.D., J.D., Dyax’s Executive Vice President and Chief Operating Officer, is leaving to pursue a senior management opportunity at a multinational pharmaceutical company, effective on March 29, 2013. 7.01 A copy of the press release announcing Dr. Magovcevic-Liebisch’s departure is furnished as Exhibit 99.1 to this report. 8.01 On March 6, 2013, Dr. Magovcevic-Liebisch sold 215,359 shares of Dyax common stock. | a50587288.htm |
| 2013-02-19 | 8-K | 2013-02-12 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | a50569033.htm |
| 2013-02-13 | 8-K | 2013-02-13 | 2.02 Results of Operations and Financial Condition | 2.02 On February 13, 2013, Dyax Corp. issued a press release announcing its financial results for the quarter ended December 31, 2012. | a50563652.htm |